Lymphoma

Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma

Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma

By

The patient's history and current blood work results indicated a dangerously high potassium level. But a meticulously handled redraw proved it false.

Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

By

Frontline treatment with rituximab plus high-dose sequential chemotherapy with autologous HSCT failed to improve progression-free or overall survival compared with R-CHOP in patients with diffuse large B-cell lymphoma.

Severe Fatigue Associated With Unemployment in Hodgkin Lymphoma Survivors

Severe Fatigue Associated With Unemployment in Hodgkin Lymphoma Survivors

By

Severe fatigue is associated with unemployment and financial problems in survivors of Hodgkin lymphoma, highlighting the need for clinicians to address fatigue in these patients.

Ciprofloxacin May Prevent Bacteremia in Patients Undergoing Auto-HSCT

Ciprofloxacin May Prevent Bacteremia in Patients Undergoing Auto-HSCT

By

Antibacterial prophylaxis with the flouroquinolone, ciprofloxacin, substantially reduced the risk of bacteremia and neutropenic fever in patients with multiple myeloma or lymphoma undergoing high-dose chemotherapy and auto-HSCT.

Carmustine Infusion Reactions Occur Despite Extending Infusion Duration

Carmustine Infusion Reactions Occur Despite Extending Infusion Duration

By

Infusion reactions during administration of high-dose carmustine as part of the BEAM conditioning regimen are common and do not appear to be reduced by modestly extending the duration of infusion or giving premedications.

Cancer-related Fatigue Common in Hodgkin Lymphoma Survivors

Cancer-related Fatigue Common in Hodgkin Lymphoma Survivors

By

There is a high incidence of severe acute and persistent cancer-related fatigue in survivors of Hodgkin lymphoma, regardless of tumor stage or treatment.

Monoclonal Antibody Shows Promise in Aggressive R/R Adult T-cell Leukemia/Lymphoma

Monoclonal Antibody Shows Promise in Aggressive R/R Adult T-cell Leukemia/Lymphoma

By

Mogamulizumab induced an encouraging response rate in patients with relapsed/refractory adult T-cell leukemia/lymphoma.

PET-CT Can Inform Decision to Omit Bleomycin in Hodgkin Lymphoma Treatment to Reduce Toxicity

PET-CT Can Inform Decision to Omit Bleomycin in Hodgkin Lymphoma Treatment to Reduce Toxicity

By

Omitting bleomycin from the treatment regimen for Hodgkin lymphoma in patients with negative findings on an interim PET scan led to a lower incidence of pulmonary toxic effects without significantly lowering treatment efficacy.

Study Confirms Lenalidomide Effective for Diffuse Large B-Cell Lymphoma

Study Confirms Lenalidomide Effective for Diffuse Large B-Cell Lymphoma

By

Lenalidomide is an effective treatment option with limited and reversible toxicities for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), a 'real-world' study has shown.

Autologous Stem Cell Transplant Safe as Standard of Care in Patients With HIV-Associated Lymphoma

Autologous Stem Cell Transplant Safe as Standard of Care in Patients With HIV-Associated Lymphoma

By

Recent results from a multicenter, phase 2 trial suggest that patients with HIV and aggressive lymphoma should receive autologous stem cell transplant as standard of care. Risk of serious complications after transplant in these patients is equal to that of patients without HIV.

aHSCT Should Be Standard of Care for HIV-Related Lymphoma

aHSCT Should Be Standard of Care for HIV-Related Lymphoma

Patients living with HIV are at high risk for lymphoma,according to recent study data, and recent autologous hematopoietic stem-cell transplantation may be preferable for these patients.

Alemtuzumab + CHOP for Peripheral T Cell Lymphoma: Higher Remission, But Not Survival

Alemtuzumab + CHOP for Peripheral T Cell Lymphoma: Higher Remission, But Not Survival

By

When added to the CHOP regimen, alemtuzumab increases remission rates in elderly patients with peripheral T cell lymphoma, final analysis of the international ACT-2 phase 3 trial presented at the ASCO 2016 Annual Meeting has shown.

Deferred Therapy Linked to Improved Survival for Newly Diagnosed Mantle Cell Lymphoma

Deferred Therapy Linked to Improved Survival for Newly Diagnosed Mantle Cell Lymphoma

By

Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma.

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

[Blood and Lymphatic Cancer: Targets and Therapy] This research examines the clinical trial data using idelalisib as monotherapy or in combination with rituximab for the treatment of indolent B-cell malignancies.

Patients With Hodgkin Lymphoma Resistant to Brentuximab Vedotin Have Poor Outcomes

Patients With Hodgkin Lymphoma Resistant to Brentuximab Vedotin Have Poor Outcomes

By

Patients with classical Hodgkin lymphoma who are resistant to the CD30-directed antibody-drug conjugate brentuximab vedotin have poor outcomes.

Gut Bacteria Could Reduce GVHD in Patients Undergoing Bone Marrow Transplantation

Gut Bacteria Could Reduce GVHD in Patients Undergoing Bone Marrow Transplantation

By

A short-chain fatty acid made by bacteria in the gut could play an important role in GVHD after allogeneic bone marrow transplant in mice. In human patients who receive bone marrow transplants, GVHD can cause severe gut damage.

Temsirolimus Effective as Salvage Treatment in Patients With Relapsed/Refractory PCNSL

Temsirolimus Effective as Salvage Treatment in Patients With Relapsed/Refractory PCNSL

By

A weekly dose of temsirolimus 75 mg was found to be active in patients with relapsed/refractory primary CNS lymphoma (PCNSL); however, only some patients achieved long-term control.

Hair, Nail Abnormalities Common With Ibrutinib Therapy

Hair, Nail Abnormalities Common With Ibrutinib Therapy

By

Hair and nail abnormalities are commonly associated with the Bruton tyrosine kinase inhibitor ibrutinib.

Reduced Intensity Salvage Allo-HCT Effective for Follicular Lymphoma

Reduced Intensity Salvage Allo-HCT Effective for Follicular Lymphoma

By

Reduced intensity allogeneic hematopoietic cell transplantation (HCT) is an effective salvage treatment strategy in patients with follicular lymphoma.

Protein Tag Improves T Cell Immunotherapy Against Lymphoma in an Animal Model

By

A new approach in T cell immunotherapy uses a small protein tag to hasten and improve the immunotherapy's ability to attack cancer cells.

Early Lineage T Cells Are Better for Immunotherapy in Pediatric Patients With ALL and Lymphoma

Early Lineage T Cells Are Better for Immunotherapy in Pediatric Patients With ALL and Lymphoma

By

Outcomes from a novel personalized cell therapy may be improved if specific subtypes of T cells are selected to attack diseases such as acute lymphoblastic leukemia and lymphoma.

NHL: Adolescent BMI, Height Linked With Subtype Risks

NHL: Adolescent BMI, Height Linked With Subtype Risks

By

Higher body weight and increased height during adolescence increase the risk for developing certain subtypes of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma.

ALK-positive anaplastic large cell lymphoma with prominent bone involvement in a 13-year-old boy

ALK-positive anaplastic large cell lymphoma with prominent bone involvement in a 13-year-old boy

[OncoTargets and Therapy] Anaplastic large cell lymphoma (ALCL) frequently involves the bone marrow, but primary or secondary involvement to the bone is rare. This article examines a case of anaplastic lymphoma kinase positive ALCL with prominent bone involvement in a young boy.

Inferior Outcomes for African Americans With Pediatric Hodgkin Lymphoma

Inferior Outcomes for African Americans With Pediatric Hodgkin Lymphoma

By

African-American pediatric patients with Hodgkin lymphoma still display a considerable survival disparity when compared to their white and Hispanic peers.

Reducing Treatment, Surveillance Barriers May Benefit Young Patients With Lymphoma

Reducing Treatment, Surveillance Barriers May Benefit Young Patients With Lymphoma

By

Identifying and reducing barriers to recommended treatment and surveillance in those at higher risk of mortality is essential.

T-cell Lymphoma Survival Varies by Racial, Ethnic Group

T-cell Lymphoma Survival Varies by Racial, Ethnic Group

By

A recent study examined the varying survival rates among US racial/ethnic patient groups with peripheral T-cell lymphoma subtypes.

Study Identifies Factors Influencing Advanced Follicular Lymphoma Outcomes

Study Identifies Factors Influencing Advanced Follicular Lymphoma Outcomes

By

Induction therapy with lenalidomide plus rituximab may result in control that is comparable to rituximab plus chemotherapy for the initial treatment.

Study Evaluates G-CSF Use in Elderly Patients With Non-Hodgkin Lymphoma

Study Evaluates G-CSF Use in Elderly Patients With Non-Hodgkin Lymphoma

By

Granulocyte colony-stimulating factors (G-CSFs) were effective in preventing outpatient encounters for fever and infection in elderly patients.

No Therapies Post-ibrutinib Appear Effective for Mantle Cell Lymphoma

No Therapies Post-ibrutinib Appear Effective for Mantle Cell Lymphoma

By

There are no therapies that appear to be uniquely effective for patients with mantle cell lymphoma who have pressed on ibrutinib.

Adolescents and Young Adults With Blood Cancers Experience Substantial Pyschological Morbidities

Adolescents and Young Adults With Blood Cancers Experience Substantial Pyschological Morbidities

By

Adolescents and young adults (AYAs) with hematologic malignancies experience significant psychological morbidities during treatment and early survivorship.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs